StreetAlpha.app
Home › Stocks › DCTH

Delcath Systems, Inc. (DCTH)

$18.79
▼ −2.34%
LAST CLOSE · NOV 20

Delcath is a medical company that makes the HEPZATO KIT and CHEMOSAT for treating cancers in the liver. It last closed at $18.79 on Nov 20, down 2.34% on the day. The next earnings report for DCTH is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, DCTH reported EPS of $0.17 on revenue of $35.1M, with revenue up 70.7% from a year ago. Over its last 8 reports the stock moved an average of 12.6% the session after earnings. Over the last 12 months DCTH insiders bought $189K of stock on the open market and sold $489K, according to SEC Form 4 filings.

AI Auto Pilots
Is DCTH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DCTH.

Key Stats

Last 12 months
Results
Revenue
$110.0M
+38.1% vs a year ago
Net income
$6.7M
+455.4% vs a year ago
EPS (diluted)
$0.16
+433.3% vs a year ago
Free cash flow
$20.1M
18.3% margin
Valuation
Market cap
$653.7M
34.8M shares
P/E
117.4
Price over 12 month EPS
Price to sales
5.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.5M
At Sep 30
Shareholder equity
$133.5M
Buybacks
$9.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.6M$3.6MFY2021FY2022: $2.7M$2.7MFY2022FY2023: $2.1M$2.1MFY2023FY2024: $37.2M$37.2MFY2024FY2025: $85.2M$85.2MFY2025

From DCTH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
$0.17
Quarter ended Sep 2026
Year ago EPS
$0.02
+750.0% on a GAAP basis
Revenue
$35.1M
+70.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: $0.03Mar '25Jun 2025: $0.07Jun '25Sep 2025: $0.02Sep '25Dec 2025: -$0.05Dec '25Mar 2026: -$0.03Mar '26Jun 2026: $0.07Jun '26Sep 2026: $0.17Sep '26Latest $0.17
Revenue by quarter
Dec 2024: $15.1MDec '24Mar 2025: $19.8MMar '25Jun 2025: $24.2MJun '25Sep 2025: $20.6MSep '25Dec 2025: $20.7MDec '25Mar 2026: $25.0MMar '26Jun 2026: $29.1MJun '26Sep 2026: $35.1MSep '26Latest $35.1M
How DCTH moved after its last 8 reports
Average move the session after a report ±12.6%
Nov 9, 2026Time not announced+35.8%
Aug 6, 2026Time not announced+22.5%
May 7, 2026Time not announced−0.2%
Feb 26, 2026Time not announced−11.8%
Jan 12, 2026After the close+1.3%
Oct 20, 2025Time not announced−4.6%
Aug 6, 2025Time not announced+1.1%
May 8, 2025Time not announced+23.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DCTHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DCTH
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DCTH

Technical Analysis

DCTH · as of the Nov 20 close · updated each morning
Uptrend

The stock is 8% above its 20 day and 14% above its 50 day average. It is 31% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 58). The nearest support is the Pivot S1 at $18.42, and the nearest resistance the Pivot at $18.88.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$22.5152 week high+19.8%
$22.51Swing high (Nov 12)+19.8%
$19.25Pivot R1+2.4%
$18.88Pivot+0.5%
$18.79Last close
$18.42Pivot S1−2.0%
$17.3420 day average−7.7%
$16.51Swing low (Aug 17)−12.1%
$16.2250 day average−13.7%
$15.46100 day average−17.7%
$12.95200 day average−31.1%
$8.1252 week low−56.8%
Indicators
RSI (14)57.76Middle of its rangeNeutral
MACD1.22Above its signal lineBullish
Stochastic61.3Middle of its rangeNeutral
ADX (14)34.3Trending up
Williams %R-44.8Oversold below −80, overbought above −20Neutral
CCI (20)36.5Oversold below −100, overbought above 100Neutral
Rate of change+25.9%Change over 10 sessionsBullish
ATR (14)$1.06Typical daily range, 5.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for DCTH

What happened before

See how DCTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DCTH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DCTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DCTHHow many large options trades hit DCTH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

DCTH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲91 buying vs 45 selling
  • ▲Held by funds +9.7 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding145122+18.9%
In funds' top 10220.0%
Held by funds59.8%50.1%+9.7 pts
New / increased36 / 5520 / 47+35.8%
Reduced / sold out32 / 1326 / 20−2.2%
Put/call ratio0.000.82−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DCTH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DCTH Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$189K3 buys · 3 insiders
Sold$489K1 sale · 1 insider
Cluster buy: 2 insiders bought $150K between Mar 2 and Mar 6.
2026-03 bought $150K2026-11 sold $489KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Bridget A MartellDirectorSale22,500$21.71$489K
Mar 6Sandra PennellCFOBuy5,533$9.04$50K
Mar 2Gerard J MichelCEOBuy11,200$8.96$100K
Nov 21, 2025John Richard SylvesterDirectorBuy4,386$8.89$39K
Nov 11, 2025Gerard J MichelCEOBuy11,500$8.53$98K
Every insider buy and sale for DCTH over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DCTH insider trades →

From SEC Form 4 filings by DCTH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DCTH is in one of them and how their past DCTH trades turned out.

DCTH in the AI portfolios
Loading…

DCTH News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DCTH in an article yet. Here's the latest on the wider market.

DCTH in the news

DCTH Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 6
Who traded DCTH · since 2017
Latest 1 filing
$1K – $15KTraded Jun 9, 2017Filed Aug 6, 2018
PersonTypeAmountTradedFiledDelay
Roger MarshallR · KSSell$1K – $15KJun 9, 2017Aug 6, 2018423 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Delcath Systems

Delcath is a medical company focused on treating cancers that have spread to the liver or started there. Its lead product is the HEPZATO KIT, a combined drug and device treatment approved in the United States for adults with uveal melanoma that has spread to the liver. In Europe, Delcath sells CHEMOSAT, a device used at medical centers to deliver treatment to the liver. Its treatments are performed by interventional radiologists, and the company is based in Queensbury, New York.

Headquarters
Queensbury, NY
Founded
1988